The Safety and Effectiveness of Warfarin Vs Apixaban in Patients with Non-Valvular Atrial Fibrillation/ Venous Thromboembolism and End-Stage Kidney Disease on Dialysis

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

时间窗: From date of enrollment until the date of first bleeding event or date of death from any cause, whichever came first, assessed up to 6 months

Safety will be assessed by Major/Minor bleeding incidents based on International Society on Thrombosis and Haemostasis (ISTH) criteria

Effectiveness: VTE

时间窗: From date of enrollment until the date of first documented VTE event or date of death from any cause, whichever came first, assessed up to 6 months

Effectiveness will be measured by VTE events based on documented radiography and/or wells score for PE/DVT

Effectiveness: Stroke

时间窗: From date of enrollment until the date of first documented Stroke event or date of death from any cause, whichever came first, assessed up to 6 months

The primary outcome is the occurrence of stroke events in the study population, confirmed through clinical evaluation (e.g., neurological assessment) and imaging (CT or MRI). Data will be collected and reported as the number of patients experiencing stroke events during the study period. The incidence will be further categorized by stroke type (ischemic or hemorrhagic) and the severity of the event, using the National Institutes of Health Stroke Scale (NIHSS) for assessment. Aggregated data will include the total number of stroke events, time to occurrence, and any associated patient outcomes (e.g., mortality, disability).